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outcomes evaluated included change from baseline in trough forced expiratory 
volume in 1 second (FEV1) and COPD exacerbations leading to hospitalizations. 
Efficacy of tiotropium was presented as the mean difference to placebo. Results: 
Difference in change from baseline in FEV1 versus placebo was evaluated in 21 RCTs. 
The relative effect of tiotropium increased over time, ranging from 0.084 to 0.150 
in 2000 (launch) and from 0.120 to 0.189 in 2012. Difference in rates of exacerba-
tions versus placebo was reported in 24 studies. The relative effect of tiotropium 
was found to decrease over time for this outcome. This trend was partly explained 
by an increase in placebo effect. ConClusions: We identified variations in the 
relative efficacy of tiotropium over time on two major outcomes for assessing drug 
relativeness effectiveness in COPD. Further research is required to understand these 
changes and the implications for evaluating the relative effectiveness of a new drug 
versus already marketed ones. Time of marketing authorization may not be the 
appropriate time to assess the relative effectiveness of a new drug.
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objeCtives: to test the efficacy of two educational interventions to improve 
the inhalation techniques in patients with Chronic Obstructive Pulmonary 
Disease. Methods: Design: Multicenter Randomised Controlled Trial 
ISRCTN60147249. Patients: 220 COPD patients (to detect a difference between 
groups of 25%, 80% statistical power, 95% confidence level, 40% expected losses), 
with inhaled treatment, written consent. Non-probabilistic consecutive sam-
pling. Allocation: Patients were randomised using block randomization into three 
cohorts: InterA, IntervB, control. Variables: Primary outcomes: Performance of cor-
rect inhalation technique. Secondary outcomes: Pick flow, Baseline dyspnea index 
(BDI), Functional status (forced spirometry). Interventions: Intervention-A: Written 
information. A leaflet with the correct inhalation technique for the main inhaler 
devices used in our area. Intervention-B: Intervention-A + individual training (by 
instructors). Follow-up: 12 month, visits: baseline, 1 month, 3rd month, 6th month, 
12th month. Statiscal analysis: Mean, frequency, 95% confidence interval at baseline. 
Number Needed to Treat for a benefit (NNT) was calculated. Intention to treat analy-
sis. Results: Predominance of males (85.5%), mean age 70.54 years (CI95%, 69.38-
71.7); FEV1(mean)= 54.2% (IC95%, 51.81-56.55), mixed respiratory pattern (62.5%). 
Severity stage: 11.4% mild, 47.4% Moderate, 41.4% Severe. Pharmacological treat-
ment: inhaled-beta2-adrenergic (81.7%); inhaled-anticholinergic (76.3%); inhaled-
corticosteroids (75.3%); mucolitycs (13.7%); xanthine (5%); oral-corticosteroids (0.9%). 
BDI: grade 2. There were no statistically significative differences between groups at 
baseline. Primary outcome: The 88.1% of patients did not perform a correct inhala-
tion technique: 88.5% with Handihaler, 83.3% with Turbuhaler, 81.7% with Accuhaler 
and 79.1% with pMDI. There were statistically significative differences between con-
trol and intervention A (p= 0.023), NNT= 8.62 (IC95%, 4.63-62.5). There were statisti-
cally significative differences between intervention B versus control (p< 0.0001), 1.74 
(IC95%, 1.47-2.17). ConClusions: The knowledge about the correct performance 
of inhalation techniques is poor in patient with COPD. The performance of a correct 
inhalation technique improves with monitor training.
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objeCtives: To evaluate the clinical effectiveness of Kanakasava and 
Swasanandam Gulika in Bronchial Asthma. Methods: A randomized single blind 
clinical study with pretest and posttest design in 2 groups’s standard and trail were 
adopted, where the patients were given treatment with specific duration with 
follow up. In total 342 patients were selected from the OPD and IPD of Muniyal 
Institute of Ayurveda Medical Sciences Manipal enrolled for the present study out 
of which 22 were dropped out from the study. Routine hematological, bio-chemical 
and urine analysis were recorded. The main Signs and Symptoms Breathlessness, 
Wheezing, cough, Sneezing, Dysponea, head ache, were taken for assessment as 
symptoms grade parameters. Peak expiatory flow rate (PEFR), Absolute Eosinophil 
count (AEC), and ESR also taken for the assessment as Laboratory parameters. Data 
obtained from the above mentioned study was statistically analyzed by using the 
Z test. Results: Kanakasava and Swasanandam Gulika provided 67.5%. relief 
in Wheezing, 75.86% relief in Dysponea , 66.07%, relief in cough, 54.78% relief 
in Sneezing and 43.22% relief in Head ache which were statistically highly sig-
nificant result p< 0.001, where as in PEFR, AEC and ESR provided 92.85%, 23% and 
35.89% relief respectively which were also statistically highly significant result 
p< 0.001. ConClusions: Kanakasava and Swasanandam Gulika appear to be 
beneficial in Bronchial Asthma along with its symptoms. Bronchial Asthma is 
considered as chronic airway inflammatory disease. The effects in every condition 
and in complications are still being evaluated.
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objeCtives: Respiratory diseases, including asthma and chronic obstructive pul-
monary disease (COPD), cause about 1 million deaths annually in the WHO European 
Region. Xanthines (e.g. theophylline, aminophylline) are recommended for treating 
severe exacerbations of COPD, when short-acting bronchodilators do not produce 
rable to mepolizumab 250mg. Active treatments were comparable regarding asthma 
exacerbations and discontinuations due to AE.
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ImPoRTanCe of eXaCeRBaTIon defInITIon
Torvinen S1, Rémuzat C2, Mzoughi O3, Plich A1, Toumi M4
1Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands, 2Creativ-Ceutical, Paris, France, 
3Creativ-Ceutical, Tunis, Tunisia, 4Aix-Marseille University, Marseille, France
objeCtives: Several monoclonal antibodies (mAb) are in development for the 
treatment of uncontrolled asthma. Network meta-analysis (NMA) will become una-
voidable to compare effectiveness of these products. It could only be performed if 
studies define outcomes similarly. The objective of this research is to review the 
consistency of exacerbation definition used in clinical trials of mAb. Methods: All 
mAbs approved or in phase II/III development in asthma were identified through 
a systematic review in Medtrack® database. Clinical trials were identified through 
the clinical.trials.gov registry. Exacerbation definition was searched for all identified 
trials through targeted literature search. Definitions were compared to the current 
European Respiratory Society, American Thoracic Society and Global Initiative for 
Asthma guidelines. Results: Sixteen mAbs were identified in phase II/III devel-
opment for asthma. Omalizumab is the only mAb approved for asthma and its 
pivotal trials occurred over 10 years ago. 95 clinical trials have been registered for 
these mAbs with 52 trials using exacerbation as a clinical endpoint. Exacerbation 
definitions were retrieved for 25 trials, among which 40% of trials defined clinical or 
clinically relevant exacerbation, 12% defined severe exacerbations and 48% defined 
exacerbation without specification of severity or clinical relevance. Definitions used 
in trials were not aligned with current guideline definitions, and were inconsistent 
between studies. Criteria used to define exacerbation included: rescue systemic 
corticosteroid, use of nebulization therapy, hospital or emergency room admission, 
unscheduled medical intervention, unscheduled outpatient visits, increased daily 
dose of rescue inhalers, worsening of symptoms, peak expiratory flow or FEV1 dete-
rioration. ConClusions: High variability of outcome definitions suggests future 
hurdles for mAb to generate comparative effectiveness through NMA. Head-to-head 
comparison of the products reaching market in the next years is not expected, and 
health technology assessment around the extent of additional benefit might be 
challenging.
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objeCtives: To assess the comparative efficacy and safety of inhaled corticoster-
oids and long-acting beta-agonist (ICS/LABA) fixed doses combination and phos-
phodiesterase-4 inhibitor for chronic obstructive pulmonary disease (COPD), using 
a Bayesian network meta-analysis. Methods: A systematic literature review was 
conducted according to NICE guidelines. Outcomes of interest included through 
forced expiratory volume in one second (FEV1), COPD exacerbations and discon-
tinuations due to adverse events (AE). Networks of evidence were based on treat-
ment- and dose-specific nodes except for budesonide/formoterol for which different 
devices were combined. Interpretation of results was based on absolute differences/
ratios and Bayesian probabilities for treatments to perform better than others (P), 
where P≤ 15% indicated a smaller effect and P≥ 85% a larger effect. Vague prior dis-
tributions were used. Selection of fixed versus random effects was based on the 
Deviance Information Criterion (DIC). Results: 6/9/5 studies reported results at 
16/26/52 weeks respectively. Analyses indicated that ICS/LABA were associated 
with higher improvement in FEV1 (D) compared to roflumilast (D: 0.050L to 0.060L, 
P≥ 94%), ICS/LABA were comparable to each other and all active treatments per-
formed better compared to placebo. In terms of COPD exacerbations, at 26 weeks, 
active treatments were overall comparable and performed better than placebo. At 
52 weeks, salmeterol/fluticasone propionate had lower COPD exacerbation rates 
than roflumilast (OR: 0.52, P= 94%). ICS/LABA were associated with lower discon-
tinuations due to AE rates compared to roflumilast (OR: 0.10 to 0.30, P≥ 98%). Among 
ICS/LABA, mometasone furoate/formoterol 200/10µg had a lower rate of discon-
tinuations compared to salmeterol/fluticasone propionate and fluticasone furo-
ate/vilanterol. ConClusions: This network meta-analysis of treatment in COPD 
suggested that ICS/LABA were associated with better efficacy and safety compared 
to roflumilast. However, roflumilast trials mainly focused on Asian patients and 
more severe populations which may have impacted the treatment effect observed.
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objeCtives: Previous studies have demonstrated substantial variation of the rela-
tive efficacy of widely used drugs over time. Changes in population characteristics or 
variation in the placebo response may be potential influencers. We used tiotropium 
as a treatment to examine this phenomenon as it has commonly been used as a 
reference treatment over time in Chronic Obstructive Pulmonary Disease (COPD). We 
aimed to assess the evolution of the relative efficacy of inhaled tiotropium against 
placebo, between launch and the latest assessment. Methods: We performed a 
systematic literature review of randomized-controlled trials (RCTs) of adults suffer-
ing from COPD in Medline from 2000 (launch) to 2012. RCTs evaluating tiotropium 
18 µg as a maintenance treatment for COPD were included in the analyses. Efficacy 
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objeCtives: Hospital readmission has been an important issue in patients with 
chronic obstructive pulmonary disease (COPD), as it reflects exacerbation of the 
disease and quality of medical care, and incurs high medical expenditures. This 
study aimed to examine pattern and economic burden of readmission, and iden-
tify factors associated with risk of readmission in patients hospitalized for COPD 
in Taiwan. Methods: The National Health Insurance claims database of a rep-
resentative sample (two million subjects) of Taiwanese population in 2005 was 
adopted for this study. Adult individuals who were discharged from acute hospitals 
for COPD in 2005 were selected and their readmission pattern one-year after dis-
charge were examined. Cox proportional hazards regression models were adopted 
to identify factors associated with risk of readmission. Results: The majority of 
the subjects was male and aged older than 65 years old. The 30-day, 3-month and 
one-year all-cause readmission rates were 28%, 46%, and 69%, respectively. The 
30-day, 3-month and one-year COPD-specific readmission rates were 10%, 17%, 
and 31%, respectively. Approximately one-fourth of the subjects were readmitted 
more than twice during the follow-up. COPD, pneumonia, and respiratory fail-
ure/insufficiency/arrest were the top three most frequent causes for readmission 
during 30 days, 3 months, or one year after discharge. In the one-yar follow-up, 
hospital readmission accounted for 73% of total healthcare expenditures. Gender, 
previous hospitalization history, comorbidities, and length of stay and hospital 
accreditation level of the index hospitalization were associated with risk of all-
cause readmission. Gender, previous hospitalization history, and length of stay and 
hospital accreditation level of the index hospitalization were associated with risk 
of COPD-specific readmission. ConClusions: This study identified patterns and 
causes of short-term and long-term readmission, and factors associated with risk 
of readmission in patients hospitalized for COPD. The information is of importance 
for planning interventions to reduce hospital readmission rate.
ReSPIRaToRy-RelaTed dISoRdeRS – Cost Studies
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objeCtives: DuoResp® Spiromax® (budesonide + formoterol fumarate dihydrate) 
is a fixed-dose combination (FDC) of inhaled corticosteroid (ICS) + long-acting 
beta agonist (LABA) in a novel dry powder inhaler (DPI). An economic model was 
developed to assess the budget impact of switching adult patients with persistent 
asthma and chronic obstructive pulmonary disease (COPD) from market-leading 
DPIs in the Italy – budesonide/formoterol Turbohaler® and fluticasone/salmeterol 
Diskus® – to DuoResp® Spiromax®. The potential cost benefit of improved inhala-
tion technique due to the innovative characteristics of the Spiromax® inhaler was 
also investigated. Methods: The eligible adult patient population was based on 
current confirmed Italian asthma and COPD diagnosis rates, with the proportion 
of patients receiving FDCs based on market research data. Costs of FDCs were 
taken from ”Farmadati Italia” database and costs of scheduled and unscheduled 
healthcare events were based on “Tariffario Regione Lombardia”, with the number 
of events estimated based on publically available UK sources. Frequency of poor 
inhalation technique, and the associated increased risk of unscheduled healthcare 
events, were taken from a large (n= 1,664) cross-sectional, Italian observational 
study. Reduction in the proportion of patients with poor inhalation technique with 
DuoResp® Spiromax® was based on assumption. Results: An estimated 196,419 
adult patients used budesonide/formoterol Turbohaler® and 505,564 fluticasone/
salmeterol Diskus® annually in Italy with 85,442 and 174,451 of these estimated 
to exhibit poor inhalation technique, respectively. Assuming a hypothetical uptake 
of DuoResp® Spiromax®reaching 10.1% in year 5 and assumed Italian prices, the 
model predicted drug cost savings totalling € 53.66 million. Furthermore, 33,948 
unscheduled healthcare events could be avoided due to the predicted improve-
ment in inhalation technique with DuoResp® Spiromax® compared with these 
DPIs, resulting in further savings of € 4.12 million. ConClusions: DuoResp® 
Spiromax® is likely to offer budgetary savings compared with market-leading 
DPIs, with further cost savings potentially resulting from improved inhalation 
technique.
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objeCtives: Chronic Obstructive Pulmonary Disease (COPD) is a prevalent dis-
ease with a significant economic burden to the UK National Health Service (NHS). 
NICE recommends maintenance treatment including inhaled bronchodilator 
medications, such as long-acting muscarinic antagonists (LAMAs) and long-acting 
beta-2-agonists (LABAs). The objective of this model was to quantify the budget 
impact to the NHS of switching patients with moderate to very severe COPD from 
tiotropium to tiotropium + olodaterol Respimat®, compared with remaining on 
tiotropium monotherapy. Methods: The model used a deterministic individual-
level Markov approach to compare scenarios with and without the introduction of 
tiotropium + olodaterol Respimat®into the health economy. Patients progressed 
through the model based on their individual FEV1 values at baseline and their 
post-treatment FEV1 value over 5 years. Relative treatment effects (estimated from a 
adequate response. The aim of this study was to compare use of xanthines in the 
treatment of chronic respiratory diseases between Serbia and the Scandinavian 
countries in the period from 2004 to 2013. Methods: The data on utilization of 
drugs for obstructive airway diseases (ATC group R03) during the ten-year period 
(2004-2013) were retrieved by a retrospective, observational, population-based study, 
from the Medicines and Medical Devices Agency of Serbia, Finnish Medicines Agency 
Fimea, Danish Statens Serum Institut and Norwegian Institute of Public Health. 
ATC/DDD methodology was applied and the results were expressed in defined 
daily doses per 1000 inhabitants per day (DID). Results: While the utilization of 
xanthines (R03DA) showed a significant tendency to decrease in all Scandinavian 
countries during the whole observed period of time (4.4-fold in Denmark, 3.46-fold 
in Norway and 2.38-fold in Finland), in Serbia on the other hand, xanthines rep-
resented the most used drugs in the R03 group, with no clear decrease tendency. 
In 2013, xanthines accounted for less than 2% of total use of drugs in R03 group 
in Finland, Norway and Denmark (1.25 DID, 0.61 DID and 0.50 DID, respectively), 
versus 26% (7.11 DID) in Serbia. ConClusions: The large differences in utiliza-
tion of xanthines between Serbia and other observed countries may suggest con-
siderable lower number of exacerbations of COPD in the Scandinavian countries 
due to better control of chronic respiratory diseases. Acknowledgement: This 
work was supported by the Provincial Secretariat for Science and Technological 
Development, Autonomous Province of Vojvodina, project No. 114-451-2458/2011 
and by the Ministry of Education, Science and Technological Development, Republic 
of Serbia, project No. 41012.
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objeCtives: A previous study was conducted in France, in 2013, to evaluate the 
physicians’ prescribing practices related to sore throat. Special attention was paid 
to the use of rapid diagnostic test (TROD). The present study aims at describing how 
sore throat is managed at the community pharmacy-level and at identifying the 
patients’ expectations concerning this condition. Methods: This was a national 
observational study conducted in community pharmacies distributed around 
France. It included two components: a questionnaire for pharmacists, administered 
by phone, and a self-administered survey submitted to adult patients spontaneously 
consulting pharmacists for sore throat. For the patient population, the data collected 
consisted in demographics, severity of sore throat and expectations. The pharma-
cists were interviewed on the type of products and advice delivered. Results: A 
total of 167 pharmacies were included in the study and 1663 patient questionnaires 
were analyzed. Data collected revealed that most patients (72%) seek pharmacists’ 
advice for sore throat in the first 48 hours after onset and expect in priority a relief of 
difficulty swallowing and/or pain. Most patients suffered from at least one asso-
ciated symptom such as running nose or headache. About 40% of patients were 
advised to consult a physician especially when sore throat lasted longer or was 
associated to a higher number of concomitant symptoms. Combinations of anti-
septic and local anesthetic represent the most frequently advised product for sore 
throat in pharmacies. TROD were not currently offered in most pharmacies (86%) but 
2 pharmacists out of 3 consider delivering it in the future depending on adequate 
training and economic return. ConClusions: The management of sore throat in 
pharmacies largely relies on over-the-counter medications. A wider availability of 
TROD could enable a better disease management and relevant referral to physicians 
in the case of bacterial involvement.
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objeCtives: Tobacco consumption is a major public health concern. Every six 
seconds someone dies due to smoking and every second smoker will die from 
smoking-related disease. Smoking double the risk of cardiovascular morbidity and 
all-cause mortality, but smoking cessation significantly reduces this risk. In order to 
best target resources for intervention, this study identified subgroups in a generaliz-
able population who have the lowest smoking cessation rates. Methods: This is a 
population-based retrospective observational study that assessed cessation rates 
among members of Clalit Health Services (Clalit), the largest health maintenance 
organization in Israel, who were aged 18 and older and reported that they were 
current smokers between 2010 and 2014. Results: There are about 642,000 Clalit 
members who reported that they were current smokers during the past between 
2010 and 2014 (consistent with the national rate of 21.1% in 2014). Of those 14.1% 
reported in 2014 that they quit smoking, versus 11.0% of the smokers reported that 
they had quit smoking in 2011. Cessation rates were lowest among women of certain 
age groups: 7.2% for those aged 18-21 and 13.8% for those aged 45-54 versus 19.9% 
for those aged 25-34, and 22.5% for those aged 65-74. Smokers from lower socioeco-
nomic status had lower smoking cessation rates compared to higher socioeconomic 
status (11.0% vs. 19.0%, respectively). ConClusions: As of 2014, only one in seven 
currents smokers reports quitting and members from low socioeconomic status and 
young and midlife-age females have the lowest smoking cessation rates. Therefore, 
healthcare providers and smoking cessation interventions should consider focus 
on those populations.
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